TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9212017

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by concurrent treatment (Arm 1): vinblastine (VB) 5 mg/M2 I.V. bolus weekly for weeks 1-5, cisplatin (DDP) 100 mg/M2 days 1 and 29, DDP 75 mg/M2 days 50, 71, and 92, with daily RT starting on day 50 (total dose 63 Gy in 34 fractions over 7 weeks).
Number of subjects: 168

Group type: COMPARATOR
Intervention: Immediate concurrent chemotherapy/radiotherapy (Arm 2): RT started on day 1 (total dose 69.6 Gy in 58 fractions of 1.2 Gy bid, 5 days per week for 6 weeks), DDP 50 mg/M2 i.v. days 1 and 8, oral VP-16 50 mg b.i.d. during the first 10 days of RT, repeated beginning day 29.
Number of subjects: 168
Study: 7936019

Group type: EXPERIMENTAL
Intervention: Azathioprine (Az) and prednisone (group Az)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Cy and prednisone (group Cy)
Number of subjects: 106
Study: 2906171

Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg twice daily for 3 days
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg twice daily for 7 days
Number of subjects: 485
Study: 29289726

Group type: EXPERIMENTAL
Intervention: Annual application of 30% SDF solution
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Three applications of 30% SDF at weekly intervals
Number of subjects: 371

Group type: COMPARATOR
Intervention: Three applications of 5% NaF varnish at weekly intervals
Number of subjects: 371
Study: 28844420

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Continuous interscalene nerve block (CISB)
Number of subjects: 70
Study: 26288992

Group type: EXPERIMENTAL
Intervention: Flat bread (FB)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control bread (CB)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pasta (PA)
Number of subjects: 10
Study: 23510291

Group type: EXPERIMENTAL
Intervention: Intervention (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anchor-based method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distribution-based method
Number of subjects: 0
Study: 20653478

Group type: EXPERIMENTAL
Intervention: Test Product (polyethylene glycol 400/propylene glycol-based lubricant eye drops with hydroxypropyl guar)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control Product (Optive Lubricant Eye Drops)
Number of subjects: 113
Study: 18161033

Group type: EXPERIMENTAL
Intervention: Fearful forms of attachment (high relationship anxiety and avoidance)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Relational avoidance
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Relational anxiety
Number of subjects: 92
Study: 17196048

Group type: EXPERIMENTAL
Intervention: Topiramate (25 to 400 mg/day over 8 weeks, continued for 4 additional weeks)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 287
Study: 14751054

Group type: EXPERIMENTAL
Intervention: i.v. Anqi
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: i.v. Anqi and oral consecutive strategy
Number of subjects: 80

Group type: COMPARATOR
Intervention: i.v. ampicillin and sulbactam
Number of subjects: 80

Group type: COMPARATOR
Intervention: i.v. cefuroxime
Number of subjects: 80
Study: 11202421

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) 300 micrograms
Number of subjects: 42

Group type: COMPARATOR
Intervention: Papaverine 30 mg + phentolamine 1 mg (Control)
Number of subjects: 42
Study: 8992678

Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (900 mg) + Metoclopramide (10 mg)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Oral Sumatriptan (100 mg)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate + Metoclopramide
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 421
Study: 1602805

Group type: EXPERIMENTAL
Intervention: Hydroxyurea and interferon alpha (IFN)
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN)
Number of subjects: 703

Group type: COMPARATOR
Intervention: Busulfan
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Prognostic evaluation
Number of subjects: 703
Study: 6547041

Group type: EXPERIMENTAL
Intervention: Gas-permeable lenses
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Thin gas-permeable lens
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Flatter fitting gas-permeable lenses
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All hard lenses studied
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control eye (no lens)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: PMMA lenses
Number of subjects: 9
Study: 31542757

Group type: EXPERIMENTAL
Intervention: CPPOpt Guided Therapy (automated CPP target based on cerebrovascular reactivity)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brain Trauma Foundation guidelines target (60-70 mm Hg)
Number of subjects: 0
Study: 29429928

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC) via three 5-minute cycles of upper limb ischemia using a blood pressure cuff
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (sham cuff)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All patients (RIPC and Control)
Number of subjects: 30
Study: 27150701

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 32
Study: 24958326

Group type: EXPERIMENTAL
Intervention: Empagliflozin 5 mg
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Empagliflozin 50 mg
Number of subjects: 547

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 547
Study: 22930812

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/day)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Fenofibrate
Number of subjects: 11
Study: 19905859

Group type: EXPERIMENTAL
Intervention: Verbal and written information
Number of subjects: 76

Group type: COMPARATOR
Intervention: Verbal information only
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both groups (Verbal and written information, Verbal information only)
Number of subjects: 76
Study: 16979793

Group type: EXPERIMENTAL
Intervention: Alcohol-based waterless scrub solution (ABWL)
Number of subjects: 1126

Group type: COMPARATOR
Intervention: Brush-based iodine solution (BBIS)
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: Alcohol-based water-aided scrub solution (ABWA)
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: All three solutions
Number of subjects: 1126
Study: 14766489

Group type: EXPERIMENTAL
Intervention: 100% KR (Knowledge of Results) during observation
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 33% KR during observation
Number of subjects: 54

Group type: COMPARATOR
Intervention: Physical practice (Control group)
Number of subjects: 54
Study: 12520092

Group type: EXPERIMENTAL
Intervention: Increase in alpha-myosin heavy chain mRNA expression
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Decrease in beta-myosin heavy chain mRNA expression
Number of subjects: 47

Group type: COMPARATOR
Intervention: Changes in beta(1)- or beta(2)-adrenergic receptor mRNA or protein
Number of subjects: 47

Group type: COMPARATOR
Intervention: Changes in sarcoplasmic reticulum Ca(2)+ ATPase mRNA expression
Number of subjects: 47

Group type: COMPARATOR
Intervention: Changes in atrial natriuretic peptide mRNA expression
Number of subjects: 47
Study: 9667346

Group type: EXPERIMENTAL
Intervention: Nutritional support (at least 10 days)
Number of subjects: 213
Study: 7806681

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy (Augmentin or clindamycin) with scaling and rootplaning
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo therapy with scaling and rootplaning
Number of subjects: 21

Group type: COMPARATOR
Intervention: Scaling and rootplaning alone
Number of subjects: 21
Study: 2588997

Group type: COMPARATOR
Intervention: 3 ml of plain 0.5% bupivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 4 ml of plain 0.5% bupivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5 ml of plain 0.5% bupivacaine
Number of subjects: 60
Study: 30454074

Group type: EXPERIMENTAL
Intervention: Level-3 operators
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Level-2 operators
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Level-1 operators
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Quantitative analysis
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Rest images available
Number of subjects: 53
Study: 28157835

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0
Study: 25736990

Group type: EXPERIMENTAL
Intervention: Reslizumab (3.0 mg/kg) every 4 weeks for 1 year
Number of subjects: 953

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 953
Study: 23179201

Group type: EXPERIMENTAL
Intervention: CHO constituent (50 g)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: New DSF (400 ml)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control product (400 ml)
Number of subjects: 34
Study: 21948951

Group type: EXPERIMENTAL
Intervention: Patient-controlled local analgesia (PCLA): self‐administration of 10 ml of ropivacaine 2 mg ml⁻¹ via the intra‐abdominal catheter for 48 h.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Thoracic epidural analgesia (TEA): infusion of 10 ml h⁻¹ of ropivacaine 1 mg ml⁻¹, fentanyl 2 μg ml⁻¹, and epinephrine 2 μg ml⁻¹ epidurally for 48 h.
Number of subjects: 50
Study: 19430766

Group type: EXPERIMENTAL
Intervention: Aqueous extract of Kava (5 tablets per day containing 250 mg of kavalactones/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15983779

Group type: EXPERIMENTAL
Intervention: ClariFlex silicone IOL
Number of subjects: 47

Group type: COMPARATOR
Intervention: AR40e hydrophobic acrylic IOL
Number of subjects: 47
Study: 19768884

Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Population service screening (organized, community-based screening)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 0
Study: 10990391

Group type: EXPERIMENTAL
Intervention: Chemonucleolysis (CN)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Automated percutaneous discectomy (APD)
Number of subjects: 22
Study: 8706305

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for 12 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Dual-energy X-ray absorptiometry (DEXA)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Total body water (TBW)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Total body potassium (TBK)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Bioelectric impedance (BIA)
Number of subjects: 25
Study: 1414179

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate and 2-chloroprocaine followed by continuous bupivacaine epidural infusion
Number of subjects: 31

Group type: COMPARATOR
Intervention: Normal saline and 2-chloroprocaine followed by continuous bupivacaine epidural infusion
Number of subjects: 31
Study: 2991708

Group type: EXPERIMENTAL
Intervention: Invited group (screening)
Number of subjects: 21000

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21000
Study: 30064725

Group type: EXPERIMENTAL
Intervention: Shoelace technique
Number of subjects: 21

Group type: COMPARATOR
Intervention: VAC wounds
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Overall primary closure
Number of subjects: 21
Study: 27125818

Group type: EXPERIMENTAL
Intervention: SSRI prescribing prior to psychological treatment
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: SSRI prescribing based on clinical characteristics
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: SSRI prescribing variation
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Medical practitioners' considerations
Number of subjects: 465
Study: 25037644

Group type: EXPERIMENTAL
Intervention: Interactive decision-aid smartphone smoking cessation application (app)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control app containing only smoking cessation information
Number of subjects: 0
Study: 23103663

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 1800
Study: 19949319

Group type: EXPERIMENTAL
Intervention: Delta‐THC
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: All drugs tested
Number of subjects: 8
Study: 17873306

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg three times a day orally) and alpha-tocopherol (300 mg twice a day orally) during radiotherapy, followed by 400 mg once a day and 300 mg once a day for 3 months after radiotherapy.
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (47 patients)
Number of subjects: 91
Study: 16164120

Group type: EXPERIMENTAL
Intervention: Bovine surfactant (Survanta)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Porcine surfactant (Surfacen)
Number of subjects: 44
Study: 11966934

Group type: EXPERIMENTAL
Intervention: 0.5% amine fluoride, 0.028% sodium fluoride, 0.03% triclosan mouthrinse
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine solution (positive control)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 12
Study: 10093981

Group type: EXPERIMENTAL
Intervention: Steroid treatment (intravenous methylprednisolone 1 g per day for 3 consecutive days at the beginning of months 1, 3, and 5, plus oral prednisone 0.5 mg/kg on alternate days for 6 months)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Supportive therapy alone
Number of subjects: 86
Study: 8527618

Group type: EXPERIMENTAL
Intervention: Omeprazole plus clarithromycin
Number of subjects: 154

Group type: COMPARATOR
Intervention: Omeprazole plus placebo
Number of subjects: 154
Study: 2257861

Group type: EXPERIMENTAL
Intervention: Drug A once daily in the evening
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Drug A b.d.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Drug B b.d.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Drug A b.d. and Drug B b.d.
Number of subjects: 24
Study: 7411244

Group type: EXPERIMENTAL
Intervention: High-fat, high-beef diet (cooked rare)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-fat, high-beef diet (cooked medium)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-fat, high-beef diet (cooked well-done)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Customary mixed-western diet (pre- and post-experimental periods)
Number of subjects: 0
Study: 31288854

Group type: EXPERIMENTAL
Intervention: Motivational interviewing appointments
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional appointments
Number of subjects: 120
Study: 28378573

Group type: EXPERIMENTAL
Intervention: BIS-guided sedation
Number of subjects: 113

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 113
Study: 25560201

Group type: COMPARATOR
Intervention: Fluoxetine (selective serotonin reuptake inhibitor) for 3 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 23440348

Group type: EXPERIMENTAL
Intervention: 80 kV/280 HU
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: 80 kV/350 HU
Number of subjects: 181

Group type: COMPARATOR
Intervention: 120 kV/350 HU
Number of subjects: 181
Study: 21679328

Group type: EXPERIMENTAL
Intervention: Skiing intervention lasting 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 18373121

Group type: EXPERIMENTAL
Intervention: 2 cc of fibrin glue intraoperatively
Number of subjects: 58

Group type: COMPARATOR
Intervention: 0.9% saline irrigation
Number of subjects: 58
Study: 16491234

Group type: EXPERIMENTAL
Intervention: Group 1 (1-year specialists)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Group 2 (5-year specialists)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Group 3 (10-year specialists)
Number of subjects: 21
Study: 14750421

Group type: EXPERIMENTAL
Intervention: Hydacorn (1 mg dihydroergotamine, 40 mg caffeine, 100 mg diphenylhydantoine)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 11094565

Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 1518

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1518
Study: 9327312

Group type: EXPERIMENTAL
Intervention: Centrifugal vortex pump (Biopump, Medtronic Biomedicus Inc, MN)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard twin roller pump
Number of subjects: 34
Study: 8238826

Group type: EXPERIMENTAL
Intervention: Fentanyl/bupivacaine (2.5 micrograms.ml‐1 of fentanyl)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sufentanil/bupivacaine (0.25 micrograms.ml‐1 of sufentanil)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fentanyl/bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sufentanil/bupivacaine
Number of subjects: 60
Study: 3519107

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Positive Expiratory Pressure (PEP)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (Triflo deep-breathing device)
Number of subjects: 43
Study: 29140155

Group type: EXPERIMENTAL
Intervention: Calmangafodipir 2 µmol/kg
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Calmangafodipir 5 µmol/kg
Number of subjects: 173
Study: 27491663

Group type: EXPERIMENTAL
Intervention: Electronically delivered, multicomponent interventions including feedback of antibiotic prescribing reports, educational tools, and a webinar for 12 months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (Control group).
Number of subjects: 0
Study: 24969367

Group type: EXPERIMENTAL
Intervention: TACT intervention package (including interactive small group workshops, feedback text messages, motivational text messages, patient information leaflets and posters)
Number of subjects: 231
Study: 20937615

Group type: EXPERIMENTAL
Intervention: 0.2 g/kg alcohol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.4 g/kg alcohol
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.0 g/kg alcohol
Number of subjects: 30
Study: 20838118

Group type: EXPERIMENTAL
Intervention: rFVIIa (200 μg/kg initially; 100 μg/kg at 1 hour and 3 hours)
Number of subjects: 573

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: rFVIIa
Number of subjects: 573
Study: 18391486

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg/day
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study: 15715599

Group type: EXPERIMENTAL
Intervention: Clindamycin (systemically or intravaginally)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12903609

Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2) as uterine distension medium
Number of subjects: 38

Group type: COMPARATOR
Intervention: Normal saline as uterine distension medium
Number of subjects: 38
Study: 10770366

Group type: EXPERIMENTAL
Intervention: Achalasia
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Reflux disease
Number of subjects: 1144

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Achalasia, no reflux, normal motility group, and controls
Number of subjects: 1144
Study: 8728351

Group type: EXPERIMENTAL
Intervention: Lisinopril (10 mg for days 1-3, 20 mg for days 4-14)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1906716

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate inhalation aerosol preparation 1
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate inhalation aerosol preparation 2
Number of subjects: 15
Study: 6343729

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation with 10 cm H2O of PEEP
Number of subjects: 139

Group type: COMPARATOR
Intervention: No PEEP
Number of subjects: 139
Study: 30947418

Group type: EXPERIMENTAL
Intervention: Angle‐Aided Circle Detection (AACD) algorithm based on the randomized Hough transform
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional Hough transform
Number of subjects: 0
Study: 28614197

Group type: EXPERIMENTAL
Intervention: Randomized Evaluation of Sedation Titration for Respiratory Failure protocol
Number of subjects: 1255

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation patients
Number of subjects: 1255

Group type: COMPARATOR
Intervention: Extracorporeal membrane oxygenation patients managed per Randomized Evaluation of Sedation Titration for Respiratory Failure protocol
Number of subjects: 1255
Study: 27464071

Group type: EXPERIMENTAL
Intervention: Watch Me Move program plus standard of care physiotherapy (n = 24)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard of care physiotherapy (n = 16)
Number of subjects: 40
Study: 24733007

Group type: EXPERIMENTAL
Intervention: Active pharmacotherapy
Number of subjects: 1295

Group type: EXPERIMENTAL
Intervention: Nicotine gum alone
Number of subjects: 1295

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 1295

Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 1295

Group type: EXPERIMENTAL
Intervention: CHRNA5‐A3‐B4 variants
Number of subjects: 1295
Study: 22685670

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (400 mg) until delivery
Number of subjects: 72

Group type: COMPARATOR
Intervention: Magnesium sulfate (control group)
Number of subjects: 72
Study: 19101111

Group type: EXPERIMENTAL
Intervention: Balloon valvuloplasty (BV)
Number of subjects: 7
Study: 17258626

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide [Ca(OH)2]
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gel (CHX)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Combination of calcium hydroxide and chlorhexidine [Ca(OH)2/CHX]
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 33